Tauriga Sciences Inc. Signs License Agreement With Targeted Medical Pharma Inc.
July 16 2014 - 2:30PM
Tauriga Sciences Inc. (OTCQB:TAUG) or ("Tauriga" or the "Company"),
a diversified life sciences company, announced today it has signed
a non-exclusive licensing agreement with Targeted Medical Pharma
Inc. (OTCQB:TRGM) to reformulate and rebrand Targeted Medical's
medical food formulations into dietary supplements as part of
Tauriga's "Cannabis Complements" product line. Tauriga's new
Cannabis Complements product line will be formally launched later
in the summer and consists of dietary supplements and other natural
wellness products that do not contain cannabis oil and that will
attempt to address cannabis-related effects, such as anxiety,
memory and cognitive functions, and appetite control. The
products to be offered under the "Cannabis Complements" line will
contain "GRAS" ingredients, the U.S. Food and Drug
Administration's designation for ingredients that are "Generally
Recognized as Safe".
Lawrence A. May, M.D., Tauriga's Chief Medical Officer and
previously head of medical affairs at Herbalife, states, "I am
enthusiastic about creating Tauriga's Cannabis Complements product
line to build our brand. We expect to first focus the
products in the 23 medical marijuana states and then more broadly
nationwide if the products are successful. Our formulations
are based on established structure-function relationships, and
these products will be consistent with the Company's commitment to
natural wellness."
Tauriga Chairman and CEO Dr. Stella M. Sung adds, "Because the
Cannabis Complements products do not contain cannabis, we believe
they represent an opportunity to market across states and to
generate immediate revenue upon launch. I believe there are
synergistic benefits between our Cannabis Complements product line
and the Honeywood/Doc Green's product line we recently acquired
through the Honeywood transaction."
The initial products Tauriga plans to introduce under the
Cannabis Complements line are Satietiva, an appetite suppressant,
and Indicalm, an antiolytic supplement for anxiety. These products
are not limited to cannabis-related effects but will be introduced
to address the concerns of the demographic.
About Tauriga Sciences, Inc.:
Tauriga Sciences, Inc. (TAUG) is a diversified life sciences
company focused on generating profitable revenues through license
agreements and the development of a proprietary technology platform
in the synthetic biology space. The mission of the Company is to
acquire and build a diversified portfolio of cutting edge
technology assets that is capital efficient and of significant
value to the shareholders. The Company's business model includes
the acquisition of licenses, equity stakes, rights on both an
exclusive and non-exclusive basis, and entire businesses.
Management is firmly committed to building lasting shareholder
value in the short, intermediate, and long terms. On July 13, 2014,
Tauriga acquired a California based topical cannabis cream company.
Please visit the Company's corporate website at
www.tauriga.com.
NON SOLICITATION:
This press release does not constitute an offer to sell or the
solicitation of an offer to buy any of these securities, nor will
there be any sale of these securities in any state or other
jurisdiction in which such offer, solicitation or sale is not
permitted. Any securities offered or issued in connection with the
above-referenced merger and/or investment have not been registered,
and will be offered pursuant to an exemption from registration.
DISCLAIMER:
Forward-Looking Statements: Except for statements of historical
fact, this news release contains certain "forward-looking
statements" as defined by the Private Securities Litigation Reform
Act of 1995, including, without limitation expectations, beliefs,
plans and objectives regarding the development, use and
marketability of products. Such forward-looking statements are
based on present circumstances and on TAUG's predictions with
respect to events that have not occurred, that may not occur, or
that may occur with different consequences and timing than those
now assumed or anticipated. Such forward-looking statements involve
known and unknown risks, uncertainties and other factors, and are
not guarantees of future performance or results and involve risks
and uncertainties that could cause actual events or results to
differ materially from the events or results expressed or implied
by such forward-looking statements. Such factors include general
economic and business conditions, the ability to successfully
develop and market products, consumer and business consumption
habits, the ability to fund operations and other factors over which
TAUG has little or no control. Such forward-looking statements are
made only as of the date of this release, and TAUG assumes no
obligation to update forward-looking statements to reflect
subsequent events or circumstances. Readers should not place undue
reliance on these forward-looking statements. Risks, uncertainties
and other factors are discussed in documents filed from time to
time by TAUG with the Securities and Exchange Commission. This
press release does not and shall not constitute an offer to sell or
the solicitation of any offer to buy any of the securities, nor
shall there be any sale of the securities, in any state or
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state. The securities have not been
registered under the Securities Act of 1933, as amended (the
"Securities Act") or any state securities laws, and may not be
offered or sold in the United States absent registration, or an
applicable exemption from registration, under the Securities Act
and applicable state securities laws.
CONTACT: Tauriga Sciences, Inc.:
Dr. Stella M. Sung,
Chairman and Chief Executive Officer
Tauriga Sciences, Inc.
www.tauriga.com
San Diego: + 1-858-353-5749
Montreal: + 1-514-840-3697
Email: ssung@tauriga.com
Targeted Medical Pharma (CE) (USOTC:TRGM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Targeted Medical Pharma (CE) (USOTC:TRGM)
Historical Stock Chart
From Apr 2023 to Apr 2024